Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DIFFERENTIAL GENE EXPRESSION OF MEDULLARY THYROID CARCINOMA REVEALS SPECIFIC MARKERS ASSOCIATED WITH GENETIC CONDITIONS.

ABSTRACT: Transcriptional analysis of 49 primary medullary thyroid carcinoma tumors. Comparisons MTCM918T vs MTC634 and MTCM918T vs MTCWT.

ORGANISM(S): Homo sapiens

PROVIDER: GSE32662 | GEO | 2013/11/26

SECONDARY ACCESSION(S): PRJNA147045

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

DIFFERENTIAL GENE EXPRESSION OF MEDULLARY THYROID CARCINOMA REVEALS SPECIFIC MARKERS ASSOCIATED WITH GENETIC CONDITIONS.

Project description:Transcriptional analysis of 49 primary medullary thyroid carcinoma tumors. Comparisons MTCM918T vs MTC634 and MTCM918T vs MTCWT. 49 (52 hybridized tumors with 3 replicates) primary Medullary Thyroid Carcinoma (MTC) cases were hybridized onto a cDNA microarray in order to identify the unique markers for specific genetic classes of MTC.

2013-11-26 | E-GEOD-32662 | biostudies-arrayexpress

microRNA profile of human medullary thyroid cancer

Project description:To identify a microRNA profile of human medullary thyroid cancer (MTC), we performed a miRNA microarray analysis exploiting 8 primary tumours and 9 paired neck nodes metastases in comparison with 3 non-neoplastic thyroid tissues.

2018-03-01 | GSE97070 | GEO

Quantitative proteomics analysis of medullary thyroid carcinoma

Project description:Medullary thyroid cancer (MTC) accounts for less than 5% of all thyroid cancers, and it is a rare neuroendocrine tumor which derives from calcitonin-secreting thyroid C cells.Given the underlying mechanism involved in MTC remain unclear, the development and the specific pathways of MTC require further investigation.here we employed the application of TMT6plex-based LC-MS/MS to identify and analyze the novel differentially-expressed proteins(DEPs) from MTC patients, To our best knowledge, it is the first study to comprehensively investigate the molecular mechanisms of MTC by proteomics technology from Chinese MTC patients’ tissues, and these DEPs identified in our study will provide a better understanding of the underlying pathophysiology of MTC, as well as may provide potential therapeutic targets for patients with MTC.

2020-05-26 | PXD005898 | Pride

Gene profile of human medullary thyroid cancer

Project description:We report gene expression profiling in a series of 17 human medullary thyroid cancer (MTC) tissues, including 8 primary tumors and 9 patient paired neck nodes metastases, in comparison with 3 non-neoplastic thyroid tissues. For the same series we have previously reported miRNA expression profiles (GSE97070 series).

2022-04-27 | GSE196264 | GEO

Gene profile of human medullary thyroid cancer

Project description:Gene profile of human medullary thyroid cancer

| PRJNA804114 | ENA

MiRNA expression profiling in human medullary thyroid carcinoma

Project description:This study aims to investigate the microRNA profile in human medullary carcinoma tissue by microarray analysis and RT-qPCR. Matched tumor and adjacent normal tissue were obtained from 24 patients and analysed using human microRNA Microarray Kit Agilent, Differentially expressed miRNAs were validated by RT-qPCR using 37 other tumors samples (validation set), Associations of microRNA expression with clinicopathological items were studied Matched tumor and adjacent normal frozen tissues were obtained from thyroid of 40 patients. Normal tissue (name with suffix S) and lesionnal tissue (name with suffix L) were hybridized on microarray.

2014-12-15 | E-GEOD-40807 | biostudies-arrayexpress

Whole genome and transcriptome analysis of medullary thyroid cancer

Project description:Medullary thyroid cancer is the neoplasm of the calcitonin-producing parafollicular cells of the thyroid gland. The hormone calcitonin acts to lower the blood calcium level, counteracting the effects of the parathyroid hormone; it can also serve as a biomarker for the presence or recurrence of medullary thyroid cancer. Surgery is the only curative treatment for this cancer. Targeted therapeutics vandetanib and cabozantinib are approved for the treatment of aggressive and metastatic tumors that are not amenable to surgery. The use of these multikinase inhibitors are supported by the observed overactivation of the RET oncoprotein in a large sub-population of medullary thyroid cancers; however, not all patients carry oncogenic alterations of this kinase. Hence, there is a need for molecular characterization of medullary tumors on the genomic scale with the aim of identifying targetable mutations. Here, we describe the genomic profiles of two medullary thyroid cancers and report the presence of a putative oncogenic BRAF fusion in one. Such alterations previously observed in other malignancies and known targets of available drugs, can benefit patients who currently have no therapy options.

| EGAS00001001473 | EGA

Transcriptional Targeting Of Oncogene Addiction In Medullary Thyroid Cancer

Project description:Transcriptional Targeting Of Oncogene Addiction In Medullary Thyroid Cancer

| PRJNA464052 | ENA

Whole Genome and Transcriptome Analysis of Medullary Thyroid Cancer - samples

Project description:Sequence data from two medullary thyroid carcinoma patients: WGS datasets generated from tumors and matched normal tissues and RNA-Seq from tumors are included.

| EGAD00001001618 | EGA

Transcription profiling of human medullary thyroid carcinoma cell line TT sunitinib or vehicle treatment time course

Project description:The aim of the study was to identify major gene expression changes associated to sunitinib response in a human medullary thyroid carcinoma (MTC)ﾠmodel.ﾠWe developed an in vitro kinetic microarray study. The humanﾠﾠMTC cell line, the TT cells, were treated with 250 nM sunitinib or vehicle during 1, 3 and 6 days. Total mRNA from sunitinib treated cells were compared to placebo treated ones for each time point.

2011-02-26 | E-TABM-929 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data